DRUGS & SUPPLEMENTS

Kinetin

Name: Kinetin drug & pharmaceuticals. Kinetin available forms, doses, prices
Creator: sdrugs.com
Published: 2021-11-11T10:10:10+00:00

How long you have been taking the medicine?

Kinetin uses

Indications and usage
Dosage and administration
Dosage forms and strengths
Contraindications
Warnings and precautions
Adverse reactions
Drug interactions
Use in specific populations
Overdosage
Description
Clinical pharmacology
Nonclinical toxicology
How supplied/storage and handling
Patient counseling information
Kinetin reviews

1 INDICATIONS AND USAGE

Kinetin is an endoglycosidase indicated as an adjuvant to increase the absorption and dispersion of other injected drugs.
for hypodermoclysis (1.2)
in subcutaneous urography for improving resorption of radiopaque agents (1.3)

1.1 Absorption and Dispersion of Injected Drugs

Kinetin (hyaluronidase injection) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs.

1.2 Hypodermoclysis

Kinetin is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration.

1.3 Subcutaneous Urography

Kinetin is indicated as an adjuvant in subcutaneous urography for improving resorption of radiopaque.

2 DOSAGE AND ADMINISTRATION

See Full Prescribing Information for all approved routes of administration.
Absorption and Dispersion of Injected Drugs
Absorption and dispersion of other injected drugs may be enhanced by adding 50 to 300 Units, most typically 150 Units of Kinetin, to the injection solution. (2.2)
Hypodermoclysis
Insert needle with aseptic precautions. With tip lying free and movable between skin and muscle, begin clysis; fluid should start in readily without pain or lump. Then inject Kinetin into rubber tubing close to needle. (2.3)
Subcutaneous Urography
The subcutaneous route of administration of urographic contrast media is indicated when intravenous administration cannot be successfully accomplished, particularly in infants and small children. With the patient prone, 75 Units of Kinetin is injected subcutaneously over each scapula, followed by injection of the contrast medium at the same sites. (2.4)

2.1 Important Administration Instructions

Do not administer Kinetin intravenously because Kinetin is enzyme is rapidly inactivated with intravenous administration.

Kinetin may be administered for infiltration use, interstitial use, intramuscular use, intraocular use, retrobulbar use, soft tissue use and subcutaneous use.

Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever the solution and container permit.

Always use aseptic precautions.

2.2 Absorption and Dispersion of Subcutaneously Injected Drugs

Absorption and dispersion of other injected drugs may be enhanced by adding 50 to 300 Units, most typically 150 Units of Kinetin, to the injection solution.

It is recommended that appropriate references be consulted regarding physical or chemical incompatibilities before adding Kinetin to a solution containing another drug.

2.3 Hypodermoclysis

Insert needle with aseptic precautions. With tip lying free and movable between skin and muscle, begin clysis; fluid should start in readily without pain or lump. Then inject Kinetin into rubber tubing close to needle.

An alternate method is to inject Kinetin under skin prior to clysis. 150 Units will facilitate absorption of 1,000 mL or more of solution. As with all parenteral fluid therapy, observe effect closely, with same precautions for restoring fluid and electrolyte balance as in intravenous injections. The dose, the rate of injection, and the type of solution (saline, glucose, Ringer's, etc.) must be adjusted carefully to the individual patient. When solutions devoid of inorganic electrolytes are given by hypodermoclysis, hypovolemia may occur. This may be prevented by using solutions containing adequate amounts of inorganic electrolytes and/or controlling the volume and speed of administration.

Kinetin may be added to small volumes of solution (up to 200 mL), such as small clysis for infants or solutions of drugs for subcutaneous injection. For infants and children less than 3 years old, the volume of a single clysis should be limited to 200 mL; and in premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight; the rate of administration should not be greater than 2 mL per minute. For older patients, the rate and volume of administration should not exceed those employed for intravenous infusion.

2.4 Subcutaneous Urography

The subcutaneous route of administration of urographic contrast media is indicated when intravenous administration cannot be successfully accomplished, particularly in infants and small children. With the patient prone, 75 Units of Kinetin (hyaluronidase injection) is injected subcutaneously over each scapula, followed by injection of the contrast medium at the same sites.

3 DOSAGE FORMS AND STRENGTHS

Injection: 150 USP Units/mL single dose vials.

Injection: 150 USP Units/mL in single-dose vials (3)

4 CONTRAINDICATIONS

Hypersensitivity

4.1 Hypersensitivity

Kinetin contraindicated in patients with known hypersensitivity to Kinetin or any other ingredient in the formulation. A preliminary skin test for hypersensitivity to Kinetin can be performed. The skin test is made by an intradermal injection of approximately 0.02 mL (3 Units) of a 150 Unit/mL solution [see Dosage and Administration (2)]. A positive reaction consists of a wheal with pseudopods appearing within five minutes and persisting for 20 to 30 minutes and accompanied by localized itching. Transient vasodilation at the site of the test, i.e., erythema, is not a positive reaction.

Discontinue Kinetin if sensitization occurs.

5 WARNINGS AND PRECAUTIONS

Spread of Localized Injection
Ocular Damage (5.2)

5.1 Spread of Localized Injection

Kinetin should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection.

Kinetin should not be used to reduce the swelling of bites or stings.

5.2 Ocular Damage

Kinetin should not be applied directly to the cornea.

6 ADVERSE REACTIONS

The most frequently reported adverse experiences have been local injection site reactions.

Kinetin has been reported to enhance the adverse events associated with co-administered drug products. Edema has been reported most frequently in association with hypodermoclysis.

Allergic reactions (urticaria, angioedema) have been reported in less than 0.1% of patients receiving Kinetin. Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely.

The most frequently reported adverse reactions have been local injections site reactions. Allergic reactions (urticarial, angioedema) anaphylactic-like reactions have been reported, rarely. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Akorn, Inc. at 1-800-932-5676, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

7 DRUG INTERACTIONS

It is recommended that appropriate references be consulted regarding physical or chemical incompatibilities before adding Kinetin to a solution containing another drug.

Furosemide, the benzodiazepines and phenytoin are incompatible with Kinetin.
Kinetin should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. (7.2)
Local Anesthetic: Kinetin hastens the onset and shortens duration of effect, increases incidence of systemic reactions. (7.3)
Large doses of salicylated, cortisone, ACTH, estrogens or antihistamines may require larger amounts of hydaluronidase for equivalent dispensing effect. (7.4)

7.1 Incompatibilities

Furosemide, the benzodiazepines and phenytoin have been found to be incompatible with Kinetin.

7.2 Drug-Specific Precautions

Kinetin should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs.

When considering the administration of any other drug with Kinetin, it is recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug.

7.3 Local Anesthetics

When Kinetin is added to a local anesthetic agent, it hastens the onset of analgesia and tends to reduce the swelling caused by local infiltration, but the wider spread of the local anesthetic solution increases its absorption; this shortens its duration of action and tends to increase the incidence of systemic reaction.

7.4 Salicylates, Cortisone, ACTH, Estrogens or Antihistamines

Patients receiving large doses of salicylates, cortisone, ACTH, estrogens or antihistamines may require larger amounts of Kinetin for equivalent dispersing effect, since these drugs apparently render tissues partly resistant to the action of Kinetin.

8 USE IN SPECIFIC POPULATIONS

Pediatric Use: The dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient. For premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight, and the rate of administration should not be greater than 2 mL per minute. Special care must be taken in pediatric patients to avoid over hydration by controlling the rate and total volume of the infusion

8.1 Pregnancy

No adequate and well controlled animal studies have been conducted with Kinetin to determine reproductive effects. Kinetin should be used during pregnancy only if clearly needed.

8.2 Labor and Delivery

Administration of Kinetin during labor was reported to cause no complications: no increase in blood loss or differences in cervical trauma were observed. It is not known whether Kinetin has an effect on the later growth, development, and functional maturation of the infant.

8.3 Nursing Mothers

It is not known whether Kinetin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Kinetin is administered to a nursing woman.

8.4 Pediatric Use

Kinetin may be added to small volumes of solution, such as small clysis for infants or solutions of drugs for subcutaneous injection. The potential for chemical or physical incompatibilities should be kept in mind [see Dosage and Administration (2)].

For infants and children less than 3 years old, the volume of a single clysis should be limited to 200 mL; and in premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight; the rate of administration should not be greater than 2 mL per minute. For older patients, the rate and volume of administration should not exceed those employed for intravenous infusion.

During hypodermoclysis, special care must be taken in pediatric patients to avoid overhydration by controlling the rate and total volume of the clysis [see Dosage and Administration (2.1)].

8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.

10 OVERDOSAGE

Symptoms of toxicity consist of local edema or urticaria, erythema, chills, nausea, vomiting, dizziness, tachycardia, and hypotension. The enzyme should be discontinued and supportive measures initiated immediately.

11 DESCRIPTION

Kinetin (hyaluronidase injection) is a preparation of purified bovine testicular Kinetin, a protein enzyme. The exact chemical structure of this enzyme is unknown.

Kinetin (hyaluronidase injection) is supplied as sterile, colorless, odorless, ready for use solution. Each vial contains 150 USP units of Kinetin per mL calcium chloride (0.4 mg), edetate disodium (1 mg), sodium chloride (8.5 mg), monobasic sodium phosphate buffer, sodium hydroxide to adjust the pH, and sterile water.

Kinetin has an approximate pH of 6.9 and an osmolality of 275 to 305 mOsm.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Kinetin is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Hyaluronic acid is also present in the capsules of type A and C hemolytic streptococci. Kinetin hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of the glucosamine moiety and C4 of glucuronic acid. This temporarily decreases the viscosity of the cellular cement and promotes diffusion of injected fluids or of localized transudates or exudates, thus facilitating their absorption.

Kinetin cleaves glycosidic bonds of hyaluronic acid and, to a variable degree, some other acid mucopolysaccharides of the connective tissue. The activity is measured in vitro by monitoring the decrease in the amount of an insoluble serum albumin-hyaluronic acid complex as the enzyme cleaves the hyaluronic acid component.

12.2 Pharmacodynamics

When no spreading factor is present, material injected subcutaneously spreads very slowly, but Kinetin causes rapid spreading, provided local interstitial pressure is adequate to furnish the necessary mechanical impulse. Such an impulse is normally initiated by injected solutions.

The rate of diffusion is proportionate to the amount of enzyme, and the extent is proportionate to the volume of solution.

12.3 Pharmacokinetics

Knowledge of the mechanisms involved in the disappearance of injected Kinetin is limited. It is known, however, that the blood of a number of mammalian species brings about the inactivation of Kinetin. Studies have demonstrated that Kinetin is antigenic; repeated injections of relatively large amounts of this enzyme may result in the formation of neutralizing anti-bodies. The reconstitution of the dermal barrier removed by intradermal injection of Kinetin (20, 2, 0.2, 0.02, and 0.002 Units/mL) to adult humans indicated that at 24 hours the restoration of the barrier is incomplete and inversely related to the dosage of enzyme; at 48 hours the barrier is completely restored in all treated areas.

Results from an experimental study, in humans that evaluated the influence of Kinetin in bone repair support the conclusion that this enzyme alone does not deter bone healing when given at the usual clinical dosage.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been performed to assess the carcinogenic or mutagenic potential of Kinetin. Kinetin is found in most tissues of the body.

Long-term animal studies have not been performed to assess whether Kinetin impaired fertility; however, it has been reported that testicular degeneration may occur with the production of organ-specific antibodies against this enzyme following repeated injections. Human studies on the effect of intravaginal Kinetin in sterility due to oligospermia indicated that Kinetin may have aided conception.

16 HOW SUPPLIED/STORAGE AND HANDLING

Kinetin (hyaluronidase injection) Bovine is supplied sterile as 150 units/mL bovine of Kinetin in a single-dose glass vial containing 1 mL.

NDC 17478-560-01 Package of 1 vial.

NDC 17478-560-06 Package of 6 vials.

NDC 17478-560-10 Package of 10 vials.

Not recommended for IV Use.

Storage: Store in a refrigerator at 2° to 8°C (36° to 46°F).

DO NOT FREEZE.

17 PATIENT COUNSELING INFORMATION

17.1 Important Precautions Regarding Kinetin

Instruct patient that Kinetin is being used to increase the dispersion and absorption of fluids or other injected drugs, as appropriate to the intended use.

17.2 What Patients Should Know About Adverse Reactions

The most frequently reported adverse reactions have been mild local injection site reactions such as redness, swelling, itching, or pain.

Anaphylactic-like reactions, and allergic reactions, such as hives, have been reported rarely in patients receiving hyaluronidases.

17.3 Patients Should Inform Their Doctors If Taking Other Medications

You may not receive furosemide, the benzodiazepines, phenytoin, dopamine and/or alpha agonists with Kinetin. These medications have been found to be incompatible with Kinetin.

If you are taking salicylates (e.g., aspirin), steroids (e.g., cortisone or estrogens) or antihistamines your doctor may need to prescribe larger amounts of Kinetin for equivalent dispersing effect.

AKORN

Manufactured by: Akorn, Inc.

Lake Forest, IL 60045

HD00N Rev. 10/15

Principal Display Panel Text for Container Label:

NDC 17478-560-01

Kinetin

(hyaluronidase

injection) Bovine,

150 USP Units/mL

1 mL

Single-Use Vial

Rx only

Not recommended

for IV use.

Principal Display Panel Text for Carton Label:

NDC 17478-560-01

Kinetin

(hyaluronidase

injection) Bovine,

150 USP Units/mL

1 mL

Single-Use Vial

Rx only

Akorn Logo

Kinetin pharmaceutical active ingredients containing related brand and generic drugs:

Hyaluronidase

Kinetin available forms, composition, doses:

Kinetin destination | category:

Human:
Enzymes
Hyaluronic acid derivatives

Kinetin Anatomical Therapeutic Chemical codes:

B06AA03 - Hyaluronidase

Kinetin pharmaceutical companies:

Bayer Schering Pharma

References

Dailymed."HYDASE (HYALURONIDASE) INJECTION, SOLUTION [AKORN, INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
"Hyaluronidase". https://pubchem.ncbi.nlm.nih.gov/su... (accessed August 28, 2018).
"kinetin". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Kinetin?

Depending on the reaction of the Kinetin after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Kinetin not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Kinetin addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

sdrugs.com conducted a study on Kinetin, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Kinetin consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.